The demographic datas of chronic granulomatous disease patients and the comparation of the clinical datas before and after interferon-gamma treatment in our country

Basit Öğe Kaydı
dc.contributor.authorFiliz, Serkan
dc.contributor.authorUygun, Dilara Fatma Kocacik
dc.contributor.authorSanal, Ozden
dc.contributor.authorCamcioglu, Yildiz
dc.contributor.authorSomer, Ayper
dc.contributor.authorBarlan, Isil
dc.contributor.authorKilic, Sebnem
dc.date.accessioned2024-02-23T14:45:47Z
dc.date.available2024-02-23T14:45:47Z
dc.date.issued2013
dc.departmentNEÜen_US
dc.description.abstractObjective: Chronic granulomatous disease (CGD) is a genetically heterogeneous primary immunodeficiency that is characterised by bacteria and fungal infections with defective phagocytosis. Interferon-gamma (INF-gamma) has diverse roles in the innate and adaptive responses. Despite several decades of work on INF-gamma treatment in CGD, contraversy remains about its use. Materials and Methods: Fifty seven patients with CGD from 14 immunology centers were enrolled to our multi-center study. A questionnaire including patients demographic datas and clinical manifestations such as infectious and granulomatous complications up to enrolment was obtained before and after INF-gamma therapy. Results: Fifty seven patients 14 (25%) girls and 34 (75%) boys aged from 2-35 years (mean age: 10.9 +/- 7.4) were enrolled. The mean age of diagnosis were 4.9 +/- 4.8 (0.1-19). 56% of the patient's family had consanguineous marriage and 60% had a primary immunodeficiency (PID) history. Ninety five of the patients were treated with trimethoprim-sulfamethoxazole (TMP-SMX) and 89.5% of them with itraconazol while 60% of them were received INF-gamma treatment. The patients receiving INF-gamma therapy tend to have lower infectious complications like severe infections, pneumonia, soft tissue infections and lymphadenitis. Aspergillus infection, tissue abcesses and granulomatous complications were also lower in this group. The annual infectious complications according to CGD subtypes, were also lower in gp91(phox) with receiving INF-gamma therapy. Conclusion: The demographic and clinical data of CGD patients in our study indicate that INF-gamma prophylaxis treatment decreases the infectious and granulomatous complications in some majority of CGD patients especially in gp91(phox)en_US
dc.identifier.endpage161en_US
dc.identifier.issn1308-9234
dc.identifier.issue3en_US
dc.identifier.startpage153en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17628
dc.identifier.volume11en_US
dc.identifier.wosWOS:000420877200004en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherBilimsel Tip Yayinevien_US
dc.relation.ispartofAstim Allerji Immunolojien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunologic Diseasesen_US
dc.subjectInterferon-Gammaen_US
dc.titleThe demographic datas of chronic granulomatous disease patients and the comparation of the clinical datas before and after interferon-gamma treatment in our countryen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu